Acteon Australia/New Zealand has expanded its distribution network across Australia and New Zealand for the Pierre Rolland portfolio of dental consumables which are now available through Gunz Dental, Medi-dent and Oraltec in New Zealand.
"Gunz Dental has played an integral part in the sales and marketing of Pierre Rolland products in both Australia and New Zealand for the past 10 years and will continue to support our business with excellent service," said Sandy Junior, General Manager, Acteon Australia/New Zealand. "The decision to expand distribution will give us a greater reach to all sectors of the market. The new network will allow us to provide efficient distribution of our products while continuing to provide exceptional customer focused solutions."
According to David Leahy, Gunz Dental's Business Unit Manager – Clinical, "Gunz Dental look forward to further building on our strong business relationship with Acteon. Our sales teams' product knowledge of the Pierre Rolland brand, developed in cooperation with Acteon over the past ten years, means we will continue to represent a great resource to dental professionals across Australia and New Zealand".
"Medi-Dent is extremely excited to be entering into this partnership with Pierre Rolland - Acteon Pharma," said Naomi Thomason, Medi-Dent's Operations Manager. "We have known about their products for some time and our sales team has been keen to work with these great products. We are confident the Pierre Rolland range products will compliment our existing offering."
Founded in 1946, Pierre Rolland Laboratories manufactures and develops innovative dental solutions. Keeping abreast of leading trends through constant contact with teaching institutions and specialists worldwide, Pierre Rolland's products are recognised for their unique benefits. Expasyl, for example, developed in collaboration with Dr Patrick Lesage (France) was the first non-cord retraction paste offered to dental practitioners and was introduced in 2000. Ten years on, Expasyl remains the undisputed category leader.
The changes are effective immediately and encompass the entire product portfolio including Expasyl, HEMOSTASYL, Riskontrol and Biosplint.